Literature DB >> 19767447

Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression.

Masaaki Miyata1, Yuki Takamatsu, Hideaki Kuribayashi, Yasushi Yamazoe.   

Abstract

Administration of the antibacterial drug ampicillin (ABPC) significantly increased hepatic bile acid concentrations. In the present study, we investigated the mechanisms for the elevation of bile acid levels in ABPC-treated mice. Hepatic microsomal cholesterol 7alpha-hydroxylation and CYP7A1 mRNA level were increased 2.0-fold in ABPC-treated mice despite higher bile acid levels in the liver and small intestinal lumen. A significant change in hepatic small heterodimer partner (SHP) mRNA level was not observed in ABPC-treated mice, whereas a marked decrease in ileal fibroblast growth factor 15 (FGF15) mRNA level was observed (3% of vehicle-treated mice). These phenomena were also observed in mice cotreated with bacitracin/streptomycin/neomycin, which are barely absorbed from the intestine. Primary bile acid contents in the small intestinal lumen were increased in ABPC-treated mice, whereas secondary bile acid, deoxycholic acid (DCA), contents were reduced to below detection limits (<0.01 micromol). In ABPC-treated mice, cotreatment with tauroDCA reversed reductions in ileal FGF15 mRNA level. Ileal SHP mRNA level was, however, not decreased in ABPC-treated mice. ABPC administration to farnesoid X receptor (Fxr)-null mice also decreased ileal FGF15 mRNA levels and secondary bile acid content in the small intestinal lumen. These results suggest that ABPC administration elevates hepatic primary bile acid synthesis, at least in part, through suppression of ileal FGF15 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767447     DOI: 10.1124/jpet.109.160093

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Authors:  Frank J Gonzalez; Changtao Jiang; Andrew D Patterson
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

3.  β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.

Authors:  Emmanuel Somm; Hugues Henry; Stephen J Bruce; Sébastien Aeby; Marta Rosikiewicz; Gerasimos P Sykiotis; Mohammed Asrih; François R Jornayvaz; Pierre Damien Denechaud; Urs Albrecht; Moosa Mohammadi; Andrew Dwyer; James S Acierno; Kristina Schoonjans; Lluis Fajas; Gilbert Greub; Nelly Pitteloud
Journal:  JCI Insight       Date:  2017-04-20

Review 4.  Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus.

Authors:  S D Udayappan; A V Hartstra; G M Dallinga-Thie; M Nieuwdorp
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 5.  New insights into bile acid malabsorption.

Authors:  Ian Johnston; Jonathan Nolan; Sanjeev S Pattni; Julian R F Walters
Journal:  Curr Gastroenterol Rep       Date:  2011-10

6.  Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice.

Authors:  Yunpeng Qi; Changtao Jiang; Jie Cheng; Kristopher W Krausz; Tiangang Li; Jessica M Ferrell; Frank J Gonzalez; John Y L Chiang
Journal:  Biochim Biophys Acta       Date:  2014-05-04

Review 7.  Cross-talk between bile acids and intestinal microbiota in host metabolism and health.

Authors:  Yang-fan Nie; Jun Hu; Xiang-hua Yan
Journal:  J Zhejiang Univ Sci B       Date:  2015-06       Impact factor: 3.066

Review 8.  Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids.

Authors:  Curtis D Klaassen; Julia Yue Cui
Journal:  Drug Metab Dispos       Date:  2015-08-10       Impact factor: 3.922

Review 9.  Bile acid signaling in metabolic disease and drug therapy.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

10.  Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4.

Authors:  Carolien Out; Jay V Patankar; Marcela Doktorova; Marije Boesjes; Trijnie Bos; Sanna de Boer; Rick Havinga; Henk Wolters; Renze Boverhof; Theo H van Dijk; Anna Smoczek; André Bleich; Vinay Sachdev; Dagmar Kratky; Folkert Kuipers; Henkjan J Verkade; Albert K Groen
Journal:  J Hepatol       Date:  2015-05-27       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.